will highlight outcomes within the high-risk diabetic subset. The
Company plans to issue a press release at this time.
Tuesday, September 4
-- TAXUS II long-term data. At 9:45 a.m., five-year clinical follow-up
results from the TAXUS II clinical trial will be presented by Antonio
Colombo, M.D., the study's principal investigator, in the Helsinki Room
(Zone 2). TAXUS II is a randomized, double-blind, controlled study of
the safety and efficacy of the TAXUS Paclitaxel-Eluting Coronary Stent,
in which two sequential cohorts of patients with standard risk, de novo
coronary artery lesions were treated with different dose formulations
versus a bare-metal stent control group. The Company plans to issue a
press release at this time.
-- Cardiac Rhythm Management Workshop Session. At 12:45 p.m., the Company
will host a workshop entitled "Cardiac Resynchronisation Therapy: all
you need to know to maximize patient follow-up," in the Cairo Room
(Zone 2). The session will address the current status of CRT, the
value of HF diagnostics after device implant, and hemodynamic
optimization during CRT.
-- Symposium on Drug-Eluting Stents. At 2:00 p.m., the Company will host
a symposium entitled "What's the evidence for using drug-eluting stents
in your patients," chaired by H.D. Glogar, M.D., and Donald S. Baim,
M.D., in the Brussels Room (Zone 4). The symposium will focus on
current treatment options for coronary artery disease, latest
challenges in ULMCA (Unprotected Left Main Coronary Artery) with PCI,
evidence-based medicine for diabetics, real world data, and future
outlook for DES.
Wednesday, September 5
-- TAXUS in Women study. Results from the TAXUS WOMAN study, a gender
specific sub-group analysis of the TAXUS II - VI trials
|SOURCE Boston Scientific Corporation|
Copyright©2007 PR Newswire.
All rights reserved